Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4908 - Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Gastric Cancer


Keun-Wook Lee


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


K. Lee1, J.W. Kim1, J.G. Kim2, B.W. Kang3, I.J. Chung4, Y.S. Hong5, T. Kim6, K.H. Lee7, D.Y. Zang8, Y.H. Ko9, E. Song10, J.H. Baek11, D. Koo3, S.Y. Oh12, H. Cho13

Author affiliations

  • 1 Internal Medicine, Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 2 Department Of Oncology/hematology,, Kyungpook National University School of Medicine, 5477 - Daegu/KR
  • 3 Department Of Internal Medicine, Kyungpook National University Hospital, 700-721 - Daegu/KR
  • 4 Internal Medicine, Chonnam National University Hwasun Hospital, 519-763 - Hwasun/KR
  • 5 Medical Oncology, The Catholic University of Korea, Seoul St. Mary’s Hospital, 06591 - Seoul/KR
  • 6 Seoul National University Hospital, Department of Internal Medicine, Seoul/KR
  • 7 Yeungnam University College Of Medicine, Department of Internal Medicine, Daegu/KR
  • 8 Division Of Hematology And Oncology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang/KR
  • 9 Department Of Internal Medicine, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 3344 - Uijeongbu/KR
  • 10 Medical Oncology, Chonbuk National University Medical School, 561180 - Jeonju/KR
  • 11 Department Of Internal Medicine, Ulsan University Hospital, 44033 - Ulsan/KR
  • 12 Oncology & Hematology, Pusan National University Yangsan Hospital, 50612 - Yangsan/KR
  • 13 Medical Department Of Genzyme, Sanofi Korea, 2345 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4908


The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).


This was a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.


Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, ‘a little’ changes (differences of 5-10 points from baseline) were observed in some of the functioning or symptom scales; none of the QOL scales showed either ‘moderate’ or ‘very much’ change (i.e., ≥11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.


This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patients with advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Clinical trial identification

Legal entity responsible for the study

Keun-Wook Lee.


Sanofi-Aventis Korea Co., Ltd.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.